Sponsor content
192 result(s) found, displaying 41 to 50
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO KwikPen tirzepatide 12.5 mg/mL solution for injection multidose pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EBGLYSS lebrikizumab 250 mg/2 mL solution for injection autoinjector (pre-filled pen).
-
Australian public assessment report (AusPar)Ebglyss (lebrikizumab) was approved to treat severe atopic dermatitis in adult and adolescent patients.
-
Australian public assessment report (AusPar)Mounjaro (tirzepatide) was approved, as an adjunct to a reduced-calorie diet and increased physical activity, for chronic weight management.
-
Prescription medicine registrationActive ingredients: tirzepatide.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL solution for injection autoinjector (pre-filled pen).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion.
-
Prescription medicine decision summaryEbglyss (lebrikizumab) is for the treatment of moderate to severe atopic dermatitis (atopic eczema) in patients older than the age of twelve.